

In the face of global health challenges,
when time is of the essence, complete solutions
must deliver efficacy, speed and reliability.

Introducing Novavax's proven and proprietary virus-like particle
(VLP) technology—a true advance over earlier approaches.

TAILOR-MADE SOLUTIONS

By including multiple proteins and lipids, Novavax can tailor vaccines to induce broad immune responses similar to natural infections.

ADDRESSING UNMET MEDICAL NEEDS

Novavax VLP technology can develop vaccines for a wide range of human infections, some of which are not currently addressed. Vaccines in development include pandemic influenza (phase II clinical trials), seasonal flu, varicella zoster (shingles) and other infectious disease targets.

SIMPLICITY, SAFETY, FLEXIBILITY

Without relying on human pathogenic viruses, Novavax offers a simple, safe and efficient manufacturing approach using ready-to-use and disposable equipment to enable production capacity at a fraction of the cost of traditional vaccine facilities.

WORLD CLASS VACCINES... FOR THE WORLD

Cutting-edge, portable manufacturing capabilities allow countries to create in-border solutions for health threats, enabling them to protect their citizens.



Faster response can save time, money and lives.

Novavax, Inc. is focused on preventing and treating a broad range of global infectious diseases through advanced, highly potent novel vaccines and a new and efficient manufacturing solution.

For more information please visit www.novavax.com

NOVAVAX

Creating Tomorrow's Vaccines